01860nam 2200529 450 991048010150332120170821175356.00-309-31271-X(CKB)3710000000336165(EBL)3379406(SSID)ssj0001468602(PQKBManifestationID)11902749(PQKBTitleCode)TC0001468602(PQKBWorkID)11536132(PQKB)10154872(MiAaPQ)EBC3379406(EXLCZ)99371000000033616520150121h20142014 uy 0engur|n|---|||||txtccrEnsuring patient access to affordable cancer drugs workshop summary /Sharyl J. Nass and Margie PatlakWashington, District of Columbia :The National Academies Press,2014.©20141 online resource (74 p.)Description based upon print version of record.0-309-31270-1 ""FrontMatter""; ""Reviewers""; ""Acknowledgments""; ""Contents""; ""Boxes, Figures, and Table""; ""Acronyms""; ""Workshop Summary""; ""Appendix: Workshop Statement of Task and Agenda""Health services accessibilityUnited StatesElectronic books.Health services accessibility362.1782Nass Sharyl J.857626Patlak MargieNational Cancer Policy Forum.Board on Health Care Services.Institute of Medicine (U.S.)Ensuring Patient Access to Affordable Cancer Drugs (Workshop)MiAaPQMiAaPQMiAaPQBOOK9910480101503321Ensuring patient access to affordable cancer drugs1997908UNINA01736nam 2200433z- 450 991069431800332120141115080351.0(CKB)5860000000031840(BIP)016979028(EXLCZ)99586000000003184020220406c2007uuuu -u- -engPublic-private partnerships innovative contracting : hearing before the Subcommittee on Highways and Transit of the Committee on Transportation and Infrastructure, House of Representatives, One Hundred Tenth Congress, first session, April 17, 20071 online resource (xiii, 347 p.) ill0-16-079673-3 Public-Private PartnershipsPublic-private sector cooperationTechnological innovationsUnited StatesTransportationUnited StatesFinanceLocal transitContracting outUnited StatesLetting of contractsUnited StatesConstruction contractsUnited StatesInfrastructure (Economics)United StatesFinancePublic-private sector cooperationTransportationLocal transitConstruction contractsInfrastructure (economics)Business & economicsTechnology & engineeringPublic-private sector cooperationTechnological innovationsTransportationFinance.Local transitContracting outLetting of contractsConstruction contractsInfrastructure (Economics)Finance.BOOK9910694318003321Public Private Partnerships2069850UNINA04431nam 2201333z- 450 9910404084403321202102123-03928-759-1(CKB)4100000011302294(oapen)https://directory.doabooks.org/handle/20.500.12854/61309(oapen)doab61309(EXLCZ)99410000001130229420202102d2020 |y 0engurmn|---annantxtrdacontentcrdamediacrrdacarrierTreatment Strategies and Survival Outcomes in Breast CancerMDPI - Multidisciplinary Digital Publishing Institute20201 online resource (264 p.)3-03928-758-3 Treatment strategies for breast cancer are wide-ranging and often based on a multi-modality approach, depending on the stage and biology of the tumour and the acceptance and tolerance of the patient. They may include surgery, radiotherapy, and systemic therapy (endocrine therapy, chemotherapy, and targeted therapy). Advances in technologies such as oncoplastic surgery, radiation planning and delivery, and genomics, and the development of novel systemic therapy agents alongside their evaluation in ongoing clinical trials continue to strive for improvements in outcomes. In this Special Issue, we publish a collection of studies looking at all forms of therapeutic strategies for early and advanced breast cancer, focusing on their outcomes, notably survival.Medicine and Nursingbicsscabemaciclibadvanced breast canceranthracycline resistanceantihormone therapyAPOBEC3Baromatase inhibitorsATMbasal-like breast cancerbiomarkerBRCAbreast cancerBreast Cancerbreast cancer survivorsbreast-conserving therapycancer treatmentcell-free DNACHEK2chemotherapycirculating tumor cellscMetcolorectal cancercomparative effectivenesscontralateral breast cancercontralateral prophylactic mastectomycyclin Edisease-free survivalductal carcinoma in situEndocrine therapyERCC1exercise characteristicsfamily historyfulvestrantgene expressiongeriatric oncologyHDAC5 inhibitorsHER2 c-erbB2HER2/neuhistone deacetylaseincidenceinfiltrating breast cancerinvasive breast cancerlactate dehydrogenaselapatinibLDHliquid biopsyLKB1LMK-235lymph-node ratiomammography screeningmastectomymetastaticmetastatic breast cancerMetforminmonitoring metastatic breast cancermutation carriersn/aNCDBnext-generation sequencingolder patientsOlder womenoutcomeoverdiagnosisPALB2palbociclibpertuzumabphysical activityphysical functionPIK3CAprognosisradiotherapyrelative survivalribociclibSEERserum biomarkersocial well-beingSrc kinasestage IVsurvivalT-DM1taxane sensitivitytrastuzumabtumor biologyyoung womenzero-inflated Poisson regression modelMedicine and NursingCheung Kwok-Leungauth1325396BOOK9910404084403321Treatment Strategies and Survival Outcomes in Breast Cancer3036843UNINA